This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HM30181A + Oral irinotecan
Description: Oratecan is an oral formulation of irinotecan.
Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan binds to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis.
Hanmi and Kinex
In December 2011, Kinex Pharmaceuticals and Hanmi Pharmaceutical announced the execution of a license agreement from Hanmi Pharmaceuticals granting Kinex Pharmaceuticals exclusive rights to their Orascovery technology (which includes a non-absorbed compound that facilitates the absorption of compounds that are usually not orally bioavailable or absorbed) and their current lead products including an oral formulation of paclitaxel.
In October 2013, Kinex and Hanmi announced the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in Malaysia, Thailand, Vietnam, the Philippines, and Indonesia.
In March 2015, Kinex Pharmaceuticals and Hanmi Pharmaceutical announced the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in India. The addition of this territory is part of the strategic plan to support Kinex and Hanmis joint effort to execute a global...See full deal structure in Biomedtracker
Partners: Hanmi Pharmaceutical Co., Ltd. Zenith Technology Corporation PharmaEssentia Corporation
Additional information available to subscribers only: